Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Optellum and Coreline Soft plan AI integration for lung nodule care
Optellum and Coreline Soft have announced plans to integrate AI to support lung nodule detection and management across international markets …
-
SCRI and MSD to broaden US oncology trial access
Sarah Cannon Research Institute (SCRI) and Merck & Co (MSD) have entered a collaboration aimed at increasing patient access to …
-
Xanadu and University of Alberta to develop quantum algorithms for cancer
Xanadu Quantum Technologies and the University of Alberta in Canada have formed a research partnership focused on advancing algorithms to …
-
Freenome’s lung cancer test receives FDA breakthrough status
Freenome has secured breakthrough device designation from the US Food and Drug Administration (FDA) for its investigational, blood-based SimpleScreen Lung …
-
Remepy secures $36m funding for hybrid drug pipeline expansion
Remepy has closed a $36m Series A financing round to accelerate its pharmaceutical co-development partnerships and expand its hybrid drug …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
Enrolment concludes in BD’s PREVENT trial of Phasix Mesh
Becton, Dickinson and Company (BD) has completed patient enrolment in the PREVENT clinical trial, which is evaluating the use of …
-
Sumitomo treats first patient in Phase I/IIa trial of DSP-3077
Sumitomo Pharma America has treated the first patient in its Phase I/IIa clinical trial of DSP-3077 for adults with non-syndromic …
-
Bracco’s VueJect contrast system secures FDA and Health Canada approvals
Bracco Imaging has obtained 510(k) clearance from the US Food and Drug Administration (FDA) and Health Canada authorisation for VueJect, …
-
First patient in Skylark Bio’s Phase I/II trial receives SKY-GJB2 gene therapy
Skylark Bio has dosed the first patient in its SONIX Phase I/II clinical trial assessing SKY-GJB2 as a potential gene …
-
Alfasigma signs agreement to acquire Nordic Group
Alfasigma has agreed to purchase Nordic Group, a move aimed at strengthening its speciality care business and expanding its reach …
-
AbCellera reports favourable Phase II data for ABCL635
AbCellera has reported encouraging top-line data from the Phase II segment of its Phase I/II study assessing ABCL635, an investigational …
-
Acarix secures approval in UAE for CADScor system
Swedish medical device company Acarix has secured regulatory approval for its CADScor system in the United Arab Emirates (UAE), a …
-
Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront
Jazz Pharmaceuticals has signed a definitive agreement to purchase Actio Biosciences in a deal that includes an upfront payment of …
-
RenovoRx reports RenovoCath’s first clinical use in sarcoma
RenovoRx has reported the first commercial clinical use of its RenovoCath device for the treatment of a sarcoma patient. The procedure …
-
Neurocrine begins Phase I trial of NBIP-‘1968 triple agonist for obesity
Neurocrine Biosciences has initiated a Phase I clinical study to evaluate NBIP-'1968, an investigational triple agonist targeting the glucagon-like peptide-1 …
